miRNA-142-3p functions as a potential tumor suppressor directly targeting FAM83D in the development of ovarian cancer.
FAM83D
GEO
IHC
microRNA-142-3p
ovarian cancer
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
22 04 2022
22 04 2022
Historique:
received:
19
01
2022
accepted:
26
03
2022
entrez:
30
4
2022
pubmed:
1
5
2022
medline:
4
5
2022
Statut:
ppublish
Résumé
FAM83D (family with sequence similarity 83, member D) is of particular interest in tumorigenesis and tumor progression. Ovarian cancer is the leading cause of cancer-related death in women all over the world. This study aims to research the association between FAM83D and ovarian cancer (OC). The gene expression data of OC and normal samples (GSE81873 and GSE27651) was downloaded from Gene Expression Omnibus (GEO) dataset. The bioinformatics analysis was performed to distinguish two differentially expressed genes (DEGs), prognostic candidate genes and functional enrichment pathways. Immunohistochemistry (IHC), Quantitative Real-time PCR (qPCR), and luciferase reporter assays were utilized for further study. There were 56 DEMs and 63 DEGs in cancer tissues compared to normal tissues. According to the km-plot software, hsa-miR-142-3p and FAM83D were associated with the overall survival of patients with OC. Besides, Multivariate analysis included that hsa-miR-142-3p and FAM83D were independent risk factors for OC patients. Furthermore, qPCR demonstrated that miRNA-142-3p and FAM83D were differentially expressed in normal ovarian tissues (NOTs) and ovarian cancer tissues (OCTs). IHC results indicated that FAM83D was overexpressed in OCTs compared with NOTs. Last but not least, luciferase reporter assays verified that FAM83D was a direct target of hsa-miRNA-142-3p in OC cells. The prognostic model based on the miRNA-mRNA network could provide predictive significance for the prognosis of OC patients, which would be worthy of clinical application. Our results concluded that miR-142-3p and its targets gene FAM83D may be potential diagnostic and prognostic biomarkers for patients with OC.
Sections du résumé
BACKGROUND
FAM83D (family with sequence similarity 83, member D) is of particular interest in tumorigenesis and tumor progression. Ovarian cancer is the leading cause of cancer-related death in women all over the world. This study aims to research the association between FAM83D and ovarian cancer (OC).
METHODS
The gene expression data of OC and normal samples (GSE81873 and GSE27651) was downloaded from Gene Expression Omnibus (GEO) dataset. The bioinformatics analysis was performed to distinguish two differentially expressed genes (DEGs), prognostic candidate genes and functional enrichment pathways. Immunohistochemistry (IHC), Quantitative Real-time PCR (qPCR), and luciferase reporter assays were utilized for further study.
RESULTS
There were 56 DEMs and 63 DEGs in cancer tissues compared to normal tissues. According to the km-plot software, hsa-miR-142-3p and FAM83D were associated with the overall survival of patients with OC. Besides, Multivariate analysis included that hsa-miR-142-3p and FAM83D were independent risk factors for OC patients. Furthermore, qPCR demonstrated that miRNA-142-3p and FAM83D were differentially expressed in normal ovarian tissues (NOTs) and ovarian cancer tissues (OCTs). IHC results indicated that FAM83D was overexpressed in OCTs compared with NOTs. Last but not least, luciferase reporter assays verified that FAM83D was a direct target of hsa-miRNA-142-3p in OC cells.
CONCLUSIONS
The prognostic model based on the miRNA-mRNA network could provide predictive significance for the prognosis of OC patients, which would be worthy of clinical application. Our results concluded that miR-142-3p and its targets gene FAM83D may be potential diagnostic and prognostic biomarkers for patients with OC.
Identifiants
pubmed: 35489022
pii: 203998
doi: 10.18632/aging.203998
pmc: PMC9085228
doi:
Substances chimiques
Cell Cycle Proteins
0
FAM83D protein, human
0
MIRN142 microRNA, human
0
MicroRNAs
0
Microtubule-Associated Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3387-3399Références
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818790508
pubmed: 30064309
EMBO Mol Med. 2016 Jan 19;8(2):73-6
pubmed: 26787653
Acta Trop. 1994 Dec;58(3-4):331-6
pubmed: 7709871
Radiat Med. 1983 Jan-Mar;1(1):65-9
pubmed: 6093198
Biochem Biophys Res Commun. 2018 Feb 12;496(3):947-954
pubmed: 29360449
Biomed Pharmacother. 2017 Dec;96:974-981
pubmed: 29221726
Arch Ital Urol Nefrol. 1968;41(3):199-217
pubmed: 5737700
Mini Rev Med Chem. 2015;15(6):467-74
pubmed: 25807941
J Cell Physiol. 2019 Feb 11;:
pubmed: 30741415
Pathobiology. 2018;85(1-2):41-49
pubmed: 29020678
Cancer Res. 2017 Oct 15;77(20):5591-5601
pubmed: 28827372
PLoS One. 2010 Apr 08;5(4):e9983
pubmed: 20386695
Ann Oncol. 2017 Apr 1;28(4):727-732
pubmed: 27993805
Cell Oncol (Dordr). 2020 Jun;43(3):395-407
pubmed: 32006253
Zentralbl Allg Pathol. 1967;110(4):306-13
pubmed: 5303304
Nature. 2001 Dec 20-27;414(6866):865-71
pubmed: 11780052
Exp Ther Med. 2018 Jun;15(6):5205-5214
pubmed: 29904404
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Oncotarget. 2015 Sep 15;6(27):24132-47
pubmed: 26125229
Leukemia. 2012 Apr;26(4):769-77
pubmed: 21979877
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Cell Mol Med. 2019 Jul;23(7):4569-4581
pubmed: 31037837
Cell Adh Migr. 2015;9(4):317-24
pubmed: 26241004
Z Tropenmed Parasitol. 1965 Oct;16(3):322-31
pubmed: 5885829
Hum Pathol. 2007 May;38(5):702-9
pubmed: 17376511
Mol Med Rep. 2019 Feb;19(2):783-791
pubmed: 30535469
Oncotarget. 2013 Dec;4(12):2476-86
pubmed: 24344117
Expert Opin Ther Targets. 2018 Sep;22(9):735-743
pubmed: 30106309
Am J Cancer Res. 2016 Nov 01;6(11):2587-2598
pubmed: 27904773
Nat Rev Genet. 2010 Sep;11(9):597-610
pubmed: 20661255
Cell Death Dis. 2018 May 29;9(6):644
pubmed: 29844410
Kango Kyoiku. 1968 Jul;9(7):12-24
pubmed: 5187584
Acta Biochim Biophys Sin (Shanghai). 2019 May 23;51(5):509-516
pubmed: 30939187
Semin Cancer Biol. 2019 Dec;59:147-160
pubmed: 31128298
Cancer Manag Res. 2018 Apr 12;10:775-785
pubmed: 29695934
Annu Rev Cell Dev Biol. 2007;23:175-205
pubmed: 17506695
Oncol Lett. 2020 Dec;20(6):286
pubmed: 33014164
Br J Cancer. 2020 Mar;122(7):943-952
pubmed: 32042067
Elife. 2014 Nov 18;3:
pubmed: 25406066
Curr Treat Options Oncol. 2020 Feb 5;21(2):17
pubmed: 32025928
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820977546
pubmed: 33302819
Thorac Cancer. 2020 Oct;11(10):2975-2982
pubmed: 32893980
Genes Chromosomes Cancer. 2004 Mar;39(3):249-56
pubmed: 14732926
J Biol Regul Homeost Agents. 2020 Feb 28;34(1):
pubmed: 32107907